EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Attention and executive functioning in children and adolescents treated for high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG)

Kristina K Hardy iD, Leanne Embry iD, John A Kairalla, Christina Sharkey, Anthony R Gioia, Danielle Griffin, Carly Berger, Hannah S Weisman, Robert B Noll, Naomi J Winick iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31179 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Kristina K Hardy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, USA. Hauptthemen laut MEDLINE: Executive Function, Methotrexate, Attention, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: St. Baldrick's Foundation, NCORP, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Survivors of childhood B‐acute lymphoblastic leukemia (B‐ALL) are at risk for difficulties with attention and executive functioning (EF) as a late effect of treatment. The present study aimed to identify treatment and demographic factors associated with risk for difficulties with EF in youth treated for high‐risk B‐ALL.

Method

Children and adolescents with B‐ALL treated on Children's Oncology Group (COG) protocol AALL0232 were randomized to high‐dose or escalating‐dose methotrexate (MTX), and either dexamethasone or prednisone during the induction phase. Neuropsychological functioning was evaluated via protocol AALL06N1, including performance‐based and parent‐report measures, for 177 participants (57% female, 81% white; mean age at diagnosis = 8.4 years; SD = 5.0) 8‐24 months following treatment completion.

Results

Mean scores for all attention and EF measures were within the average range, with no significant differences as a function of MTX delivery or steroid treatment (all p > 0.05). In multivariable models, participants with US public insurance exhibited significantly greater parent‐reported EF difficulties than those with US private or non‐US insurance ( p ≤ 0.05). Additionally, participants diagnosed under 10 years of age performed significantly more poorly on measures of attention (i.e., continuous performance task, p ≤ 0.05) and EF (i.e., verbal fluency and tower planning task, p ≤ 0.05).

Conclusions

For survivors of pediatric B‐ALL, treatment‐related factors were not associated with attention or EF outcomes. In contrast, outcomes varied by demographic characteristics, including age and insurance type, an indicator of economic hardship. Future research is needed to more directly assess the contribution of socioeconomic status on cognitive outcomes in survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Executive FunctionMethotrexateAttentionAntineoplastic Combined Chemotherapy ProtocolsPrecursor Cell Lymphoblastic Leukemia-LymphomaDexamethasoneHumansFemaleChildMaleAdolescentChild, PreschoolPrednisoneFollow-Up StudiesCancer SurvivorsNeuropsychological Tests

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaexecutive functioninglate effects of cancer treatment

Substanzen

MethotrexateDexamethasonePrednisone

Autor:innen und Institutionen

  • Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, USA.
  • Departments of Pediatrics and Psychiatry, The George Washington University School of Medicine, Washington, USA.
  • Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
  • Department of Psychology, The Catholic University of America, Washington, USA.
  • Neuropsychology Department, Kennedy Krieger Institute, Baltimore, USA.

ORCID-Profile: Kristina K Hardy, Leanne Embry, Naomi J Winick

Förderung

  • St. Baldrick's Foundation
  • NCORP
  • NCI NIH HHS
  • NCTN Operations Center, the NCTN Statistics and Data Center
  • National Cancer Institute

Zitieren

APA

Hardy, K. K., Embry, L., Kairalla, J. A., Sharkey, C., Gioia, A. R., Griffin, D., Berger, C., Weisman, H. S., Noll, R. B., & Winick, N. J. (2024). Attention and executive functioning in children and adolescents treated for high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31179

Vancouver

Hardy KK, Embry L, Kairalla JA, Sharkey C, Gioia AR, Griffin D, et al. Attention and executive functioning in children and adolescents treated for high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31179

BibTeX
@article{Hardy2024,
  author = {Hardy, Kristina K and Embry, Leanne and Kairalla, John A and Sharkey, Christina and Gioia, Anthony R and Griffin, Danielle and Berger, Carly and Weisman, Hannah S and Noll, Robert B and Winick, Naomi J},
  title = {Attention and executive functioning in children and adolescents treated for high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG)},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31179}
}
Kostenlos starten →